Combination targeted therapy (encorafenib and binimetinib) followed by combination immunotherapy (ipilimumab and nivolumab) is also being investigated in 270 patients with unresectable or metastatic melanoma with BRAF V600 mutation in the randomized, multicentre, comparative phase II Combination of Targeted Therapy (Encorafenib and Binimetinib) Followed by Combination of Immunotherapy (Ipilimumab and Nivolumab) vs. Immediate Combination of Immunotherapy in Patients With Unresectable or Metastatic Melanoma With BRAF V600 Mutation: an EORTC Randomized Phase II Study (EBIN) study [56]. Here, BRAF is linked to metastatic melanoma.